{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:47:16Z","timestamp":1788425236520,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymgme.2023.108122","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T13:51:57Z","timestamp":1703425917000},"page":"108122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data"],"prefix":"10.1016","volume":"141","author":[{"given":"Fran","family":"Rohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary O.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lilienstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"van Calcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleigh","family":"Whitehall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.108122_bb0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2023.108122_bb0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.ymgme.2023.108122_bb0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108122_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.108122_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/gim.2013.179","article-title":"Recommendations for the nutrition management of phenylalanine hydroxylase deficiency","volume":"16","author":"Singh","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108122_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","article-title":"PKU dietary handbook to accompany PKU guidelines","volume":"15","author":"MacDonald","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.108122_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ymgme.2016.04.008","article-title":"Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach","volume":"118","author":"Singh","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0040","author":"Southeast Regional Genetics Network and Genetic Metabolic Dietitians International"},{"key":"10.1016\/j.ymgme.2023.108122_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-023-02751-0","article-title":"Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations","volume":"18","author":"Cunningham","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.108122_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ymgme.2021.10.001","article-title":"Natural history of children and adults with phenylketonuria in the NBS-PKU Connect registry","volume":"134","author":"Kenneson","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0060","first-page":"39","article-title":"Living with phenylketonuria in adulthood: the PKU ATTITUDE study","volume":"16","author":"Cazzorla","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0065","first-page":"57","article-title":"Living with phenylketonuria: lessons from the PKU community","volume":"17","author":"Ford","year":"2018","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0070","first-page":"561","article-title":"Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments","volume":"10","author":"Ashe","year":"2019","journal-title":"Front. Psychol."},{"key":"10.1016\/j.ymgme.2023.108122_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2010.05.017","article-title":"Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence","volume":"101","author":"Enns","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000479746","article-title":"Effects of inadequate amino acid mixture intake on nutrient supply of adult patients with phenylketonuria","volume":"71","author":"Hochuli","year":"2017","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10545-006-0108-3","article-title":"Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)","volume":"29","author":"Hvas","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl","key":"10.1016\/j.ymgme.2023.108122_bb0090","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ymgme.2013.09.009","article-title":"Micronutrient status in phenylketonuria","volume":"110","author":"Robert","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102459","article-title":"Nutritional and metabolic characteristics of UK adult phenylketonuria patients with varying dietary adherence","volume":"11","author":"Green","year":"2019","journal-title":"Nutrients."},{"key":"10.1016\/j.ymgme.2023.108122_bb0100","first-page":"58","article-title":"Nutritional management of phenylketonuria","volume":"68","author":"MacLeod","year":"2010","journal-title":"Ann. Nestle Eng."},{"key":"10.1016\/j.ymgme.2023.108122_bb0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2014.11.011","article-title":"A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria","volume":"114","author":"Burton","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2023.108122_bb0115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.108122_bb0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.108122_bb0125","author":"BioMarin Pharmaceutical Inc."},{"key":"10.1016\/j.ymgme.2023.108122_bb0130","author":"Australian Government Therapeutic Goods Administration"},{"key":"10.1016\/j.ymgme.2023.108122_bb0135","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2023.108122_bb0140","author":"Health Canada"},{"key":"10.1016\/j.ymgme.2023.108122_bb0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2018.03.003","article-title":"Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation Phase 3 clinical trial","volume":"124","author":"Harding","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0155","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","article-title":"Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria","volume":"21","author":"Longo","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108122_bb0160","article-title":"Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase","volume":"28","author":"Rocha","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0165","article-title":"Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics","volume":"28","author":"Adams","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2022.08.001","article-title":"Pegvaliase dosing in adults with PKU: requisite dose for efficacy decreases over time","volume":"137","author":"Hollander","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","article-title":"Palynziq clinic: one year and 43 patients later","volume":"133","author":"Lah","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0180","article-title":"First 1.5 years of pegvaliase clinic: experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymgme.2021.06.002","article-title":"Nutrition status of adults with phenylketonuria treated with pegvaliase","volume":"133","author":"Viau","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1203\/00006450-197007000-00002","article-title":"Malnutrition with early treatment of phenylketonuria","volume":"4","author":"Hanley","year":"1970","journal-title":"Pediatr. Res."},{"issue":"Suppl","key":"10.1016\/j.ymgme.2023.108122_bb0195","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ymgme.2013.10.006","article-title":"Man made disease: clinical manifestations of low phenylalanine levels in an inadequately treated phenylketonuria patient and mouse study","volume":"110","author":"Pode-Shakked","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0200","series-title":"Dietary Intakes and Adverse Events in Pegvaliase-Treated Phenylketonuria Adults Who Had Low Blood Phenylalanine Concentrations, Society for the Study of Inborn Errors of Metabolism 2019 Annual Symposium, Rotterdam, The Netherlands","author":"Longo","year":"2019"},{"key":"10.1016\/j.ymgme.2023.108122_bb0205","author":"BioMarin Pharmaceutical Inc."},{"key":"10.1016\/j.ymgme.2023.108122_bb0210","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/cts.13043","article-title":"Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria","volume":"14","author":"Qi","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgme.2023.108122_bb0215","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","article-title":"A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase","volume":"96","author":"Sarkissian","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2023.108122_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","article-title":"Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria","volume":"41","author":"Bilder","year":"2016","journal-title":"Dev. Neuropsychol."},{"key":"10.1016\/j.ymgme.2023.108122_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/nu11050995","article-title":"Over restriction of dietary protein allowance: the importance of ongoing reassessment of natural protein tolerance in phenylketonuria","volume":"11","author":"Pinto","year":"2019","journal-title":"Nutrients."},{"key":"10.1016\/j.ymgme.2023.108122_bb0230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.copbio.2016.10.009","article-title":"Designing medical foods for inherited metabolic disorders: why intact protein is superior to amino acids","volume":"44","author":"Ney","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymgme.2023.108122_bb0235","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jn\/56.2.253","article-title":"The phenylalanine requirement of the normal infant","volume":"56","author":"Snyderman","year":"1955","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymgme.2023.108122_bb0240","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ajcn\/67.4.640","article-title":"Twenty-four-hour L-[1-(13)C]tyrosine and L-[3,3-(2)H2]phenylalanine oral tracer studies at generous, intermediate, and low phenylalanine intakes to estimate aromatic amino acid requirements in adults","volume":"67","author":"Basile-Filho","year":"1998","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ymgme.2023.108122_bb0245","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/ajcn\/83.6.1331","article-title":"The daily phenylalanine requirement of healthy Indian adults","volume":"83","author":"Kurpad","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ymgme.2023.108122_bb0250","article-title":"Nutritional status of adults with phenylketonuria on pegvaliase: a 15-month prospective study","volume":"37","author":"Viau","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108122_bb0255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","article-title":"Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria","volume":"125","author":"Burton","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108122_bb0260","article-title":"Telogen effluvium: a review of the literature","volume":"12","author":"Asghar","year":"2020","journal-title":"Cureus."}],"updated-by":[{"DOI":"10.1016\/j.ymgme.2024.108613","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:29:19Z","timestamp":1747322959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223007527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1096719223007527"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108122","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Analysis of phase 3 clinical trial data","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108122"}}